Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Donepezil on Sedation and Other Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with drowsiness/sedation caused by opiate for \> 3 days and its intensity more or equal to 3/10 (0 to 10 scale; 0 = no sedation, 10=worst possible sedation).~2. Patient receiving a regular dose of a strong opioid for the treatment of cancer pain, and no dose changes or dose change within 50% for at least 48 hours.Regular administration, defined as short acting opioids oral or parenteral every 4 hours around clock, slow release oral opioids every 12 hs or 24 hs, or transdermal opioids every 72 hours. Strong opioids include morphine, hydromorphone, methadone, fentanyl, and oxycodone.~3. Patient with relatively intact cognition defined by the Mini Mental State Examination according to age and educational level. A score of 24 or above is usually considered normal.~4. Patient willing to engage in follow up visit with a nurse by phone on day 2-7 (each day), 11 and 15 of the study and to return for follow up visit on day 8 of treatment. If patient is unable to come to clinic, assessment will be performed through telephone.~5. Sexually active females at risk of being pregnant with a negative urine pregnancy test~6. Written consent form signed.~7. Patients are 18 years or older~8. Concurrent radiation treatment (defined as 10 or less fractions for a palliative indication) is allowed~9. Concurrent chemotherapy is allowed, if the first two cycles have been well tolerated (defined as no grade 3 or 4 non-hematological toxicity)~Exclusion Criteria:~1. Major contraindication to donepezil i.e. hypersensitivity to donepezil or piperidine derivatives.~2. Patients in whom a major change in opiate dose, analgesia requirements, anesthetic procedures or general anesthetic is expected over the next seven days.~3. Treatment with anti-cholinergic agents (i.e., glycopyrrolate)~4. Patients taking Methylphenidate.~5. Patients with tube feeding (due to difficulty of accurate assessing some of the symptoms such as appetite and anorexia).~6. History of ongoing arrhythmia causing a rhythm other than a sinus rhythm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: ACTIVE_COMPARATOR): Oral Donepezil 5 mg daily x 7 days
- daily x 7 days (Type: PLACEBO_COMPARATOR): Placebo tablet daily x 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).